$25.68
7.40% today
Nasdaq, Apr 02, 10:17 pm CET
ISIN
US92686J1060
Symbol
VKTX
Sector
Industry

Viking Therapeutics, Inc. Stock price

$23.91
-1.79 6.97% 1M
-38.09 61.44% 6M
-16.33 40.58% YTD
-55.59 69.92% 1Y
+20.78 663.90% 3Y
+19.56 449.66% 5Y
+14.95 166.85% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
-0.24 0.99%
ISIN
US92686J1060
Symbol
VKTX
Sector
Industry

Key metrics

Market capitalization $2.68b
Enterprise Value $1.78b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.03
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-150.92m
Free Cash Flow (TTM) Free Cash Flow $-87.79m
Cash position $902.61m
EPS (TTM) EPS $-1.01
P/E forward negative
P/S forward 1,610.31
EV/Sales forward 1,069.42
Short interest 28.90%
Show more

Is Viking Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Viking Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Viking Therapeutics, Inc. forecast:

16x Buy
94%
1x Hold
6%

Analyst Opinions

17 Analysts have issued a Viking Therapeutics, Inc. forecast:

Buy
94%
Hold
6%

Financial data from Viking Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.35 0.35
21% 21%
-
-0.35 -0.35
21% 21%
-
- Selling and Administrative Expenses 49 49
33% 33%
-
- Research and Development Expense 102 102
59% 59%
-
-151 -151
50% 50%
-
- Depreciation and Amortization 0.35 0.35
21% 21%
-
EBIT (Operating Income) EBIT -151 -151
50% 50%
-
Net Profit -110 -110
28% 28%
-

In millions USD.

Don't miss a Thing! We will send you all news about Viking Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Viking Therapeutics, Inc. Stock News

Positive
The Motley Fool
about 13 hours ago
Viking Therapeutics (VKTX -0.99%) is operating in one of the highest-growth pharma areas around. I'm talking about the weight loss drug market -- one that Morgan Stanley analysts say may multiply by 15 to surpass $100 billion later this decade.
Positive
MarketBeat
2 days ago
In the world of upstart pharmaceuticals and healthcare companies, timing is everything. These firms often struggle for an extended period of time before becoming profitable, but when they see success with a new product—or even clinical trial results suggesting a new product could be on the horizon—they can experience huge rallies in a very short period of time.
Positive
Investors Business Daily
7 days ago
Viking Therapeutics stock skidded Wednesday despite the "encouraging" speed with which the company enrolled patients in an obesity study. The post Viking Therapeutics Skids Despite 'Rapid' Enrollment In Obesity Pill Study appeared first on Investor's Business Daily.
More Viking Therapeutics, Inc. News

Company Profile

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Head office United States
CEO Brian Lian
Employees 36
Founded 2012
Website www.vikingtherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today